Lenograstim versus filgrastim in mobilization before autologous hematopoietic stem cell transplantation in patients with multiple myeloma and lymphoma - Single center experience
| Autor: | Soykan Bicim, Selim Gök, Ömer Faruk Bahçecioğlu, Mehmet Ali Erkurt, Emin Kaya, Mustafa Ozgul, Irfan Kuku, Ilhami Berber, Ahmet Sarici |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Platelet Engraftment Filgrastim Lymphoma medicine.medical_treatment Hematopoietic stem cell transplantation 030204 cardiovascular system & hematology Lenograstim 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Autologous transplantation Humans Prospective Studies Autografts Lenalidomide Aged Neutrophil Engraftment business.industry Hematopoietic Stem Cell Transplantation Hematology Middle Aged Hematopoietic Stem Cell Mobilization Transplantation Female business Multiple Myeloma 030215 immunology medicine.drug |
| Zdroj: | Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis. 60(4) |
| ISSN: | 1473-0502 |
| Popis: | Objective Peripheral blood stem cell transplantation is frequently used in the treatment of various hematological malignancies after intensive chemotherapy. The primary aim of our study is to compare the amount of collected CD34+ cells and engraftment times in patients mobilized with filgrastim or lenograstim. Material and Methods Demographic and clinical data of multiple myeloma (MM) and lymphoma patients who underwent autologous transplantation and mobilized with G-CSF (filgrastim or lenograstim) without chemotherapy were collected retrospectively. Results One hundred eleven MM and 58 lymphoma patients were included in the study. When mobilization with filgrastim and lenograstim was compared in MM patients, there was no significant difference in neutrophil and thrombocyte engraftment times of lenograstim and filgrastim groups (p = 0.931 p = 0.135, respectively). Similarly, the median number of CD34+ cells collected in patients receiving filgrastim and lenograstim was very similar (4.2 × 106/kg vs 4.3 × 106/kg, p = 0.977). When compared with patients who received lenalidomide before transplantation and patients who did not receive lenalidomide, the CD34+ counts of the two groups were similar. However, neutrophil and platelet engraftment times in the group not receiving lenalidomide tended to be shorter (p = 0.095 and p = 0.12, respectively). When lymphoma patients mobilized with filgrastim and lenograstim were compared, neutrophil engraftment time (p = 0.498), thrombocyte engraftment time (p = 0.184), collected CD34+ cell counts (p = 0.179) and mobilization success (p = 0.161) of the groups mobilized with filgrastim and lenograstim were similar. Conclusion The superiority of the two agents to each other could not be demonstrated. Multi-center prospective studies with larger numbers of patients are needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect